Somewhat Favorable News Coverage Likely to Impact Meridian Bioscience (VIVO) Stock Price
Media stories about Meridian Bioscience (NASDAQ:VIVO) have trended somewhat positive recently, Alpha One Sentiment reports. The research firm, a unit of Accern, ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Meridian Bioscience earned a news impact score of 0.22 on Alpha One’s scale. Alpha One also gave media stories about the company an impact score of 78 out of 100, indicating that recent news coverage is likely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have impacted Alpha One Sentiment Analysis’s analysis:
- Zacks: Analysts Anticipate Meridian Bioscience, Inc. (VIVO) Will Post Earnings of $0.19 Per Share (americanbankingnews.com)
- Research Reports Initiation on Diagnostic Substances Stocks — P – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
- Meridian Bioscience, Inc.: ECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection (finanznachrichten.de)
- Meridian Bioscience : ECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection (4-traders.com)
- Meridian Bioscience (VIVO) Earning Somewhat Positive News Coverage, AlphaOne Reports (americanbankingnews.com)
Meridian Bioscience (NASDAQ:VIVO) traded up 0.36% during trading on Thursday, reaching $13.75. The company had a trading volume of 263,031 shares. The stock has a market capitalization of $580.28 million, a P/E ratio of 19.64 and a beta of 1.00. The stock has a 50 day moving average of $13.31 and a 200-day moving average of $15.58. Meridian Bioscience has a 12-month low of $10.75 and a 12-month high of $21.49.
Meridian Bioscience (NASDAQ:VIVO) last posted its earnings results on Wednesday, January 25th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by $0.05. The business had revenue of $46.80 million for the quarter, compared to analyst estimates of $51.15 million. Meridian Bioscience had a net margin of 15.13% and a return on equity of 18.51%. The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.21 earnings per share. On average, analysts forecast that Meridian Bioscience will post $0.66 earnings per share for the current fiscal year.
Several equities analysts recently issued reports on the company. Zacks Investment Research raised Meridian Bioscience from a “sell” rating to a “hold” rating in a research report on Tuesday, January 17th. Piper Jaffray Companies set a $9.00 price objective on Meridian Bioscience and gave the company a “sell” rating in a research report on Wednesday, January 25th. CL King assumed coverage on Meridian Bioscience in a research report on Tuesday, March 28th. They issued a “neutral” rating on the stock. Finally, Craig Hallum cut Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Tuesday, January 31st. Two analysts have rated the stock with a sell rating and five have assigned a hold rating to the stock. Meridian Bioscience presently has an average rating of “Hold” and an average target price of $15.33.
In other Meridian Bioscience news, EVP Lawrence Baldini bought 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 26th. The stock was bought at an average cost of $12.70 per share, for a total transaction of $50,800.00. Following the completion of the transaction, the executive vice president now directly owns 106,934 shares of the company’s stock, valued at approximately $1,358,061.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.30% of the company’s stock.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.